E-Mail
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to research published today.
A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which will help doctors and patients to decide on the best treatment options.
They used samples from a previous trial funded by Cancer Research UK to look at the levels of two proteins, known as AREG and EREG, which are produced by some colorectal cancers.
Algorithms driven by AI enabled the researchers to show that patients with higher levels of these proteins received significant benefit from a treatment which inhibits a different protein involved in cancer cell growth, known as EGFR. Of equal importance, patients with low levels of the proteins did not benefit from the treatment.
E-Mail
IMAGE: West Mato Volcano erupting in 2009. Image courtesy of the National Oceanic and Atmospheric Administration view more
Credit: Image courtesy of the National Oceanic and Atmospheric Administration
Volcanic eruptions deep in our oceans are capable of extremely powerful releases of energy, at a rate high enough to power the whole of the United States, according to research published today.
Eruptions from deep-sea volcanoes were long-thought to be relatively uninteresting compared with those on land. While terrestrial volcanoes often produce spectacular eruptions, dispersing volcanic ash into the environment, it was thought that deep marine eruptions only produced slow moving lava flows.
E-Mail
The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.
Researchers from the Wellcome Sanger Institute, Newcastle University, University College London, University of Cambridge, EMBL s European Bioinformatics Institute (EMBL-EBI) and their collaborators within the Human Cell Atlas initiative, found raised levels of specific immune cells in asymptomatic people. They also showed people with more serious symptoms had lost these protective cell types, but gained inflammatory cells. These differences in the immune response could help explain serious lung inflammation and blood clotting symptoms, and could be used to identify potential targets for developing therapies.
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
April 15, 2021 02:00 ET | Source: Sitryx Therapeutics Sitryx Therapeutics LONDON, UNITED KINGDOM
Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation, today announces the appointment of Iain Kilty, Ph.D., as its Chief Scientific Officer.
Iain will lead the development and execution of the Company’s research strategy and advancement of the Company’s pipeline of disease-modifying therapeutics in immuno-oncology and immuno-inflammation.
Awakn Launches Digital Unit and Signs Agreement with the University of Exeter to Improve Addiction Treatment Through Artificial Intelligence and Big Data digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.